This approach will help in the development of regenerative medicine at clinics without a cell processing center. The aim of this study was to prepare and validate the Lithuanian version of the STOP-BANG questionnaire and evaluate its correlation with polysomnography results. In this study, we included patients ≥ 18 years of age who underwent overnight polysomnography between January 1 in 2018 and January 1 in 2019. All patients completed the STOP-BANG questionnaire before polysomnography. To assess the adequacy of the questionnaire, we used contingency tables and areas under the receiver operating characteristic curve. The study included 236 patients. The mean age of the patients was 55.2 ± 11.5 years and 159 (68%) were men. The mean apnea-hypopnea index for the entire study group was 33.8 ± 28.4, and the mean STOP-BANG score was 5.4 ± 1.6 points. Moderate (0.3-0.7, p < 0.05) correlations were found between the STOP-BANG questionnaire scores and all measured objective anthropometric and polysomnography parameters. The questionnaire's Cronbach's alpha score was 0.408. Based on the analysis of the ROC curves, the cut-off STOP-BANG score of 3 points showed a sensitivity of 87% and a specificity of 50% (AUC = 0.717) for the identification of any OSA. The positive predictive value (PPV) for an identification of any OSA at a cut-off point of 3 was 96%, and the negative predictive value (NPV) was 26%. The linguistic and cultural adaptation of the Lithuanian version of the STOP-BANG questionnaire was carried out in accordance with international recommendations. The Lithuanian version of theSTOP-BANG questionnaire is characterized by high sensitivity and average specificity in diagnosing OSA. The linguistic and cultural adaptation of the Lithuanian version of the STOP-BANG questionnaire was carried out in accordance with international recommendations. The Lithuanian version of the STOP-BANG questionnaire is characterized by high sensitivity and average specificity in diagnosing OSA. Since disagreement has been found between an objective sleep propensity measured by sleep onset latency (SOL) and subjective sleepiness assessment measured by the Epworth sleepiness scale (ESS) score, distinct underlying causes and consequences were suggested for these two sleepiness measures. We addressed the issue of validation of the ESS against objective sleepiness and sleep indexes by examining the hypothesis that these two sleepiness measures are disconnected due to their differential relationship with the antagonistic drives for sleep and wake. The polysomnographic records of 50-min napping attempts were collected from 27 university students on three occasions. Scores on the first and second principal components of the electroencephalographic (EEG) spectrum were calculated to measure the sleep and wake drives, respectively. Self-assessments of subjective sleepiness and sleep were additionally collected in online survey of 633 students at the same university. An ESS score was disconnected with the polysomnographic and self-assessed SOL in the nap study and online survey, respectively. An ESS score but not SOL was significantly linked to the spectral EEG measure of the sleep drive, while SOL but not ESS showed a significant association with the spectral EEG measure of the opposing wake drive. Each of two sleepiness measures was validated against objective indicators of the opposing sleep-wake regulating processes, but different underlying causes were identified for two distinct aspects of sleepiness. A stronger sleep drive and a weaker opposing drive for wake seem to contribute to a higher ESS score and to a shorter SOL, respectively. Each of two sleepiness measures was validated against objective indicators of the opposing sleep-wake regulating processes, but different underlying causes were identified for two distinct aspects of sleepiness. A stronger sleep drive and a weaker opposing drive for wake seem to contribute to a higher ESS score and to a shorter SOL, respectively. Continuous positive airway pressure (CPAP) therapy reduces circulating intercellular adhesion molecule 1 (ICAM-1) in adults with obstructive sleep apnea (OSA). https://www.selleckchem.com/products/Perifosine.html ICAM-1 levels may affect the daytime sleepiness and elevated blood pressure associated with OSA. We evaluated the association of changes from baseline in ICAM-1 with changes of objective and subjective measures of sleepiness, as well as 24-h ambulatory blood pressure monitoring (ABPM) measures, following 4 months of CPAP treatment. The study sample included adults with newly diagnosed OSA. Plasma ICAM-1, 24-h ABPM, Epworth Sleepiness Scale (ESS), and psychomotor vigilance task (PVT) were obtained at baseline and following adequate CPAP treatment. The associations between changes in natural log ICAM-1 and changes in the number of lapses on PVT, ESS score, and 24-h mean arterial blood pressure (MAP) were assessed using multivariate regression models, controlling for a priori baseline covariates of age, sex, BMI, race, site, smoking status, physical activity, anti-hypertensive medications, AHI, and daily hours of CPAP use. Among 140 adults (83% men),mean (± SD) body mass index (BMI) was 31.5± 4.2 kg/m , and apnea-hyopnea index (AHI) was 36.8± 15.3 events/h.Sleepiness measures, although not ICAM-1 or ABPM measures, improved significantly following CPAP treatment. We observed no statistically significant associations between the change in ICAM-1 and changes in sleepiness, MAP, or other ABPM measures. Changes in ICAM-1 levels were not related to changes in sleepiness or ABPM following CPAP treatment of adults with OSA. Future work should explore whether or notother biomarkers may have a role in mediating these treatment outcomes in adults with OSA. Changes in ICAM-1 levels were not related to changes in sleepiness or ABPM following CPAP treatment of adults with OSA. Future work should explore whether or not other biomarkers may have a role in mediating these treatment outcomes in adults with OSA. Obstructive sleep apnea (OSA) is defined as the cessation of respiration due to recurrent and partial or complete blockade of the upper airways during sleep. Nocturnal hypoxemia due to OSA may accompany these conditions, with significant negative impact on the life quality of patients leading to mental and/or sexual dysfunction. OSA as a cause of sexual dysfunction in women has been subject to very little research. The goal of this study was to examine the effect of OSA on sexual functions in women suffering from this disorder. Patientswith OSA were categorized into two groups, those with and those without sexual dysfunction. When women with OSA and healthy women were compared, age (p< 0.001), body mass index (BMI) (p< 0.001), Beck Anxiety Inventory (BAI) (p< 0.001), Beck Depression Inventory (BDI) (p= 0.001), there was a significant difference in the ArizonaSexual Experience Scale (ASEX), (p= 0.02). When women with OSA were compared in terms of sexual dysfunction, a significant difference was found in apnea-hypopnea index (AHI) (p= 0.